High affinity antibodies against HMGB1 and methods of use thereof
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
1. An isolated antibody or an antigen-binding fragment thereof that specifically binds a human HMGB1 polypeptide or antigenic fragment thereof comprising:
a) a light chain variable region having the 3 CDRs of the light chain of the antibody S6, SEQ ID NO:9, and a heavy chain variable region, wherein the heavy chain variable region comprises 3 CDRs; or
b) a heavy chain variable region having the 3 CDRs of the light chain of the antibody S6, SEQ ID NO:11, and a light chain variable, wherein the light chain variable region comprises 3 CDRs; or
c) a light chain variable region having the 3 CDRs of the light chain of the antibody S6, SEQ ID NO:9, and a heavy chain variable region having the 3 CDRs of the heavy chain of the antibody S6, SEQ ID NO:11.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region having the 3 CDRs of the light chain of the antibody S6, SEQ ID NO:9, and a heavy chain variable region having the 3 CDRs of the heavy chain of the antibody S6, SEQ ID NO:11.
3. An isolated antibody or an antigen-binding fragment thereof comprising a light chain variable region from the antibody S6, SEQ ID NO:9 and a heavy chain variable region from the antibody S6, SEQ ID NO:11.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of: a monoclonal antibody, a chimeric antibody; a single-chain Fv (scFv); an Fab fragment; and a F(ab′) fragment.
5. The antibody or antigen-binding fragment thereof of claim 3 , wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of: a monoclonal antibody, a chimeric antibody; a single-chain Fv (scFv); an Fab fragment; and a F(ab′) fragment.
6. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof is a human antibody or an antigen binding fragment thereof.
7. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof has a pI of between 6.5 and 9.5 and has a Tm of between 65 degrees Celsius and 95 degrees Celsius.
8. The antibody or antigen-binding fragment thereof of claim 3 , wherein said antibody or antigen-binding fragment thereof has a pI of between 6.5 and 9.5 and has a Tm of between 65 degrees Celsius and 95 degrees Celsius.
9. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof inhibits the release of proinflammatory cytokine from a vertebrate cell treated with an HMGB1 polypeptide.
10. The antibody or antigen-binding fragment thereof of claim 9 , wherein the cytokine is selected from the group consisting of: IL-1β, TNF-α, and IL-6.
11. The antibody or antigen-binding fragment thereof of claim 3 , wherein said antibody or antigen-binding fragment thereof inhibits the release of a proinflammatory cytokine from a vertebrate cell treated with an HMGB1 polypeptide.
12. The antibody or antigen-binding fragment thereof of claim 11 , wherein the cytokine is selected from the group consisting of: IL-1β, TNF-α, and IL-6.
13. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof when administered to a rodent is at least 30% protective in at least one rodent sepsis model.
14. The antibody or antigen-binding fragment thereof of claim 13 , wherein the rodent sepsis model is a rodent cecal ligation and puncture model.
15. A composition comprising the antibody or antigen-binding fragment thereof of claim 3 in a pharmaceutically acceptable excipient.
16. A composition comprising the antibody or antigen-binding fragment thereof of claim 6 in a pharmaceutically acceptable excipient.